FB7011 + FB7013

FB7011 and FB7013 are small interfering RNA (siRNA) therapeutic candidates developed by Frontier Biotechnologies for the treatment of IgA nephropathy (IgAN). FB7013 is a single-target siRNA that specifically inhibits mannose-binding lectin-associated serine protease 2 (MASP-2), a key enzyme in the complement lectin pathway. FB7011 is a dual-target siRNA designed for 'dual-pathway interception,' simultaneously targeting both MASP-2 and complement factor B (CFB), which is central to the alternative complement pathway. Both candidates are administered subcutaneously and are designed to provide potent, long-lasting suppression of complement activation to prevent glomerular damage. In February 2026, GSK acquired the global development and commercialization rights for these programs.